Shaker Investments LLC OH Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO

Shaker Investments LLC OH trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 50.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,990 shares of the biopharmaceutical company’s stock after selling 19,085 shares during the quarter. Shaker Investments LLC OH’s holdings in Halozyme Therapeutics were worth $1,393,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $32,000. Employees Retirement System of Texas purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $34,000. Asset Management One Co. Ltd. bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $98,000. EverSource Wealth Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the period. Finally, ST Germain D J Co. Inc. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $142,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.7%

Halozyme Therapeutics stock opened at $68.87 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The firm has a market cap of $8.10 billion, a P/E ratio of 14.50, a P/E/G ratio of 0.37 and a beta of 0.95. The business has a fifty day moving average of $67.34 and a two-hundred day moving average of $65.49. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.27 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Monday, December 22nd. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Finally, Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $75.10.

Insider Buying and Selling at Halozyme Therapeutics

In other news, COO Cortney Caudill sold 4,263 shares of the firm’s stock in a transaction dated Saturday, November 1st. The shares were sold at an average price of $65.19, for a total value of $277,904.97. Following the sale, the chief operating officer directly owned 12,737 shares in the company, valued at approximately $830,325.03. This trade represents a 25.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $71.60, for a total transaction of $59,356.40. Following the completion of the transaction, the director directly owned 42,123 shares in the company, valued at approximately $3,016,006.80. The trade was a 1.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 85,661 shares of company stock valued at $6,036,837. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.